Albemarle — Jul 30, 2025 release

Specialties and Ketjen Outlook Considerations Specialties outlook reflects volume growth in key end markets led by pharma, automotive, and oilfield, partially offset by weakness in building and construction. Ketjen outlook assumes strong fluidized catalytic cracking (FCC) volume offset by lower clean fuel technologies (CFT) volume due to order timing. Segment FY 2025E Specialties net sales $1.3 - $1.5 billion Specialties adjusted EBITDA $210 - $280 million Ketjen net sales $1.0 - $1.1 billion Ketjen adjusted EBITDA $120 - $150 million Other Corporate Outlook Considerations Albemarle expects its 2025 capital expenditures to be between $650 and $700 million, down approximately 60% from $1.7 billion in 2024. This level of spending reflects in part a timing impact and a continued prioritization on sustaining existing assets and resources. Reduced corporate costs reflects cost savings and foreign exchange gains to date. Other Corporate FY 2025E Capital expenditures $650 - $700 million Depreciation and amortization $630 - $670 million Adjusted effective tax rate (a) (40)% - 25% Corporate costs (b) $40 - $70 million Interest and financing expenses $180 - $210 million Weighted-average common shares outstanding (diluted) 118 million (a)    Adjusted effective tax rate dependent on lithium market prices and geographic income mix (b)    FY 2025E outlook includes FX impact in the first half of 2025 Cash Flow and Capital Deployment Cash from operations of $538 million in the first half of 2025 increased $73 million compared to the prior-year period. We now expect to achieve positive free cash flow f